 |
News and Events 
Press Releases
BackRESEARCH TRIANGLE PARK, N.C. - March 30, 2010 - Drug discovery company, SCYNEXIS, Inc. announced today that management will present an overview on the Company's lead anti-hepatitis C virus (HCV) candidate, SCY-635, at the upcoming Canaccord Adams' Hepatitis C Conference on Thursday, April 1, 2010 at 11:15 am ET at the Peninsula Hotel in New York City.
SCY-635 is a novel cyclophilin inhibitor and represents a new pharmacological class of inhibitors of HCV replication. SCY-635 has shown strong single-agent antiviral activity in a Phase 1b clinical study and has also demonstrated promising antiviral activity when combined with a wide range of mechanistically diverse anti-HCV agents. SCYNEXIS expects to initiate a Phase 2 study for SCY-635 in the second quarter of 2010.
About SCY-635 and SCYNEXIS' Cyclophilin Inhibitor Platform
SCY-635 represents a new class of therapeutic agents for the treatment of HCV infection. SCY-635 is the first candidate in a novel class of non-immunosuppressive cyclophilin inhibitors owned by SCYNEXIS. Cyclophilins are a family of enzymatic proteins that assist in the folding and transport of other proteins synthesized within a cell. Cyclophilin inhibitors, such as Cyclosporine A, have been used for decades for the prophylaxis of organ rejection in transplant patients. Scientists at SCYNEXIS have synthesized derivatives of Cyclosporine A in which cyclophilin binding activity is separated from calcineurin binding activity (which mediates immunosuppression). A growing body of scientific evidence indicates that non-immunosuppressive analogs of Cyclosporine A may have applications in multiple therapeutic areas. Cyclophilins play a central role in the pathophysiology of chronic viral infection, neurodegenerative diseases and malignant transformation. Cyclophilin inhibition therefore represents an attractive target for drug discovery and development.
About SCYNEXIS
SCYNEXIS is a premier drug discovery and development company delivering effective and innovative drug pipeline solutions to pharmaceutical and global health partners. The Company, which is located in Research Triangle Park, North Carolina, is also focused on developing a proprietary internal pipeline based on cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases. Please visit our website at www.scynexis.com.
Company Contact:
Terry Marquardt
SCYNEXIS, Inc.
919-544-8603
terry.marquardt@scynexis.com
Media Relations:
Sarah Cavanaugh
MacDougall Biomedical Communications
781-235-3060
scavanaugh@macbiocom.com
Copyright © 2010. SCYNEXIS, INC